|
|
|
< Previous page
|
|
|
| Related Keyword：禮來 , 試驗 , 抗體藥 , 新冠 , 疫苗 |
| Related Concept：禮來暫停抗體藥物臨床測試 , 美國嬌生 , 新冠肺炎臨床試驗 , 新冠疫苗安全 , 輝瑞疫苗最快 |
| |
| 美國禮來藥廠基於安全隱患暫停抗體治療臨床試驗- RTHK ＠ 2020-10-15T20: |
| 繼美國制藥公司強生暫停新型冠狀病毒疫苗試驗後，另一間美國藥廠禮來（Eli Lilly）亦宣布，叫停獲政府支持的一種抗體療法臨床試驗。 禮來發言人說，出於審慎 ... |
| Keyword：禮來 試驗 抗體藥 |
| Concept：禮來暫停抗體藥物臨床測試 , 美國嬌生 |
| 新冠肺炎：禮來公司以安全為由暫停抗體藥臨床測試 ＠ 2020-10-15T08: |
| 繼美國藥廠強生公司（Johnson & Johnson）後，獲美國政府贊助、跨國藥廠禮來公司（Eli Lilly. |
| Keyword：禮來 試驗 新冠 |
| Concept：禮來暫停抗體藥物臨床測試 , 新冠肺炎臨床試驗 |
| ＠ 2020-10-14T16: |
|
| Keyword：禮來 |
| Concept： |
| 副作用少「近乎完美」 輝瑞疫苗爭取最快10月中面世 ＠ 2020-09-13T08: |
| 新冠肺炎疫情持續，全球均努力研發疫苗應對，有不少藥廠以將疫苗進行臨床試驗。德國生物技術公司BioNTech的創辦人兼行政總裁薩恩（Ugur Sahin）較早前接. |
| Keyword：疫苗 |
| Concept：新冠疫苗安全 , 輝瑞疫苗最快 |
|
|
< Previous page
|
|
|
|
|
| Disclaimer :
In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.
|
|
